ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
110,54
-0,02
(-0,02%)
Geschlossen 01 Juli 10:00PM

Gilead Sciences Inc (GIS) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
110,54
( -0,02% )
Gebot
110,38
Fragen
110,64
Volumen
895
109,34 Tagesbereich 110,94
92,36 52-Wochen-Bereich 132,16
Marktkapitalisierung
Handelsende
110,56
Handelsbeginn
110,90
Letzte Trade
5
@
110.54
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
7.106.255 €
Ausgegebene Aktien
1.241.569.874
Dividendenrendite (LTM)
3,19 (2,50%)
Kurs-Gewinn-Verhältnis
17,39
Gewinn pro Aktie (EPS)
7,35
Erlöse (LTM)
29,74B
Nettogewinn (LTM)
9,22B

Über Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Foster City, United States
Gegründet
1987
Gilead Sciences Inc is listed in the Healthcare sector of the Tradegate (DE) with ticker GIS. The last closing price for Gilead Sciences was 110,56 €. Over the last year, Gilead Sciences shares have traded in a share price range of 92,36 € to 132,16 €.

Gilead Sciences currently has 1.241.569.874 shares in issue. The market capitalisation of Gilead Sciences is 137,24 € billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 17.39.

GIS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.020.0180962721679110.52112.92108.621716110.48900338DE
4-2.1-1.86434659091112.64113.8104.862388108.60093641DE
12-10.4-8.59930544071120.94122.9104.861919111.84360023DE
264.764.49990546417105.78132.1699.862380117.15902262DE
5216.0817.023078551894.46132.1692.362338109.21348343DE
15640.3657.50926189870.18132.1657.18382184.25889755DE
26053.7994.784140969256.75132.1652.06406776.60951663DE

GIS - Frequently Asked Questions (FAQ)

What is the current Gilead Sciences Inc share price?
The current share price of Gilead Sciences Inc is 110,54 €
How many Gilead Sciences Inc shares are in issue?
Gilead Sciences Inc has 1.241.569.874 shares in issue
What is the market cap of Gilead Sciences Inc?
The market capitalisation of Gilead Sciences Inc is EUR 137,24B
What is the 1 year trading range for Gilead Sciences Inc share price?
Gilead Sciences Inc has traded in the range of 92,36 € to 132,16 € during the past year
What is the PE ratio of Gilead Sciences Inc?
The price to earnings ratio of Gilead Sciences Inc is 17,39
What is the cash to sales ratio of Gilead Sciences Inc?
The cash to sales ratio of Gilead Sciences Inc is 5,34
What is the registered address of Gilead Sciences Inc?
The registered address for Gilead Sciences Inc is 333 Lakeside Drive, Foster City, California, 94404
What is the Gilead Sciences Inc website address?
The website address for Gilead Sciences Inc is www.gilead.com
Which industry sector does Gilead Sciences Inc operate in?
Gilead Sciences Inc operates in the Pharmaceuticals sector

GIS Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen